UCSF Helen Diller Family Comprehensive Cancer Center | Strategic Alliance Partners

Studies that continue to shed light on the optimal use of sipuleucel-T in men with prostate cancer were presented at the 2013 Genitourinary Cancers Symposium.

The key to advancements in chemotherapy treatment for patients with metastatic breast cancer most likely will come through a better understanding of their underlying tumor biology.

Pamela Munster, MD, from UCSF Helen Diller Family Comprehensive Cancer Center, discusses results from a phase II study that examined vorinostat in combination with tamoxifen for endocrine therapy-resistant breast cancer.

Agents that target the c-MET pathway may prove to have significant benefit when combined with inhibitors of angiogenesis.